MTOR and non-small cell lung carcinoma: Mutant KRAS increased about by three‐fold the activity of an ACSL3 promoter reporter (pGL3‐ACSL3luc) depending on the mTOR signaling pathway, resulting in an upregulation of fatty acid metabolism in NSCLC [26].